Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone

Luo, Yi; Tang, Fan; Wang, Yitian; Zhou, Yong; Li, Min; Zhang, Wenli; Shi, Rui; Duan, Hong; Tu, Chongqi

doi:10.2147/cmar.s161871

Cited by 11 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of their patients with metastatic disease progression was found during an average of 28.6 months follow-up period. Three patients showed partial response and four patients got stable disease after denosumab treatment [8]. An open-label, phase II study divided GCTB patients into 3 cohorts.…”

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Multiple Pulmonary Metastases of Giant Cell Tumor of Bone with expression of VEGFR-2 Successfully Treated by Denosumab and Apatinib: A Rare Case Report

Gong¹,

Luo²,

Wang³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Giant cell tumor of bone (GCTB) is a rare benign but locally aggressive bone tumor. It has a high tendency for local recurrence, which may increase the occurrence of lung metastasis. Currently, the treatment of pulmonary metastases of GCTB is controversial. Denosumab is the preferred regimen for unresectable metastatic lesions, but there are no alternative treatment options when denosumab is resistant. So far, no case reports of metastatic GCTB treated with denosumab and apatinib have been published. Case presentation: This is a case report of a 26-year-old female who experienced right knee pain for over 6 months. Radiography and computed tomography revealed osteolytic bony destruction in the proximal right tibia. Using histological, radiological, and clinical techniques, a diagnosis of GCTB was achieved. Meanwhile, the immunohistochemical stain-identified the tumor cells were positive for vascular endothelial growth factor receptor 2 (VEGFR-2). After intralesional curettage of the primary tumor and wide resection of local recurrence surgeries, she developed recurrent hemoptysis. Chest computed tomography (CT) images showed multiple pulmonary nodules. She was administrated denosumab therapy but disease progression was confirmed after four months of treatment. She then received denosumab and apatinib therapy for 24 months, after a partial response was achieved.Conclusions: We depict a case of multiple pulmonary metastases of GCTB successfully controlled by denosumab and apatinib therapy. VEGFR-2 may be an effective therapeutic target for GCTB with pulmonary metastasis when denosumab is ineffective.

show abstract

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Multiple Pulmonary Metastases of Giant Cell Tumor of Bone with expression of VEGFR-2 Successfully Treated by Denosumab and Apatinib: A Rare Case Report

Gong¹,

Luo²,

Wang³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…A critical review of these published studies identified 60 studies that met the inclusion criteria for the present meta-analysis ( Table 1 ). 11 , 12 , 44 , 60 - 116 The www.clinicaltrials.gov website showed 7 ongoing studies of denosumab in the treatment of GCTB. The majority of the studies examined for this meta-analysis were case reports, case series studies, and nonrandomized, uncontrolled, open-label phase II studies ( Figure 2 ).…”

Section: Resultsmentioning

confidence: 99%

“…et al 77 (2018) Scoccia nti et al 78 (2018) Yang et al 79 (2018) Luo et al 80 (2018) Chen et al 81 (2018) Rutkow ski et al 82 (2018) Errani et al 83 (2018) Ji et al 86 (2017) Deveci et al 93 increase the risk of new malignant diseases (eg, osteosarcoma) because of immunosuppression. 91,118 The most common location of GCTB on participants from all study types in this evaluation was the lower limbs, followed by the upper limbs and sacrum, which is in agreement with the data of another study.…”

Section: Agarwalmentioning

confidence: 99%

Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis

Yayan

2020

Cancer Control

View full text Add to dashboard Cite

Background: Denosumab is a human monoclonal antibody that has been used successfully in the treatment of giant cell tumors of bone. These tumors are rare and, in principle, benign, but they are highly aggressive, locally advanced, osteolytic bone tumors that can metastasize to the lungs. Denosumab is an effective treatment when these tumors cannot be surgically removed or when surgical resection is likely to lead to severe morbidity (eg, loss of limbs or joints). The aim of this systematic review and meta-analysis was to investigate patients with giant cell tumors of bone who experienced tumor progression during treatment with denosumab and to compare them with patients who experienced reduction of their giant cell tumors of bone during treatment with denosumab. Methods: Embase, Cochrane Library, and MEDLINE/PubMed databases were searched for trials submitted by January 7, 2020, that reported the efficacy and safety of denosumab in patients with giant cell tumors of bone. Results: Sixty studies were reviewed, involving a total of 1074 patients who had giant cell tumors of bone and were treated with denosumab. Of the 60 studies, 58% of the patients were from case series studies, 39% from open-label phase II studies, and 3% from case reports. The response rate for denosumab as a treatment for giant cell tumors of bone was 97.5%, with statistical significance ( P < .0001). Pain in the limbs was statistically the most common adverse event for denosumab treatment in case series studies ( P < .0001). No treatment-related deaths occurred in the reviewed studies. Conclusion: Cumulative evidence supports the addition of surgery to optimal medical therapy with denosumab to reduce tumor size, clinical symptoms, and mortality among patients with giant cell tumors of bone.

show abstract

“…This result is very consistent to work reported by others. 25 The pH in the tumor microenvironment is weakly acidic, ie, 6.8, while in endosomes and lysosomes is much more acidic, ie, 5.5. 26 Therefore, it is logical to assume that the released DOX in tumors is more than in normal tissues at a physiological pH of 7.4.…”

Section: Discussionmentioning

confidence: 99%

<p>Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy</p>

Dorjsuren¹,

Chaurasiya²,

Ye³

et al. 2020

IJN

View full text Add to dashboard Cite

Background One major limitation of cancer chemotherapy is a failure to specifically target a tumor, potentially leading to side effects such as systemic cytotoxicity. In this case, we have generated a cancer cell-targeting nanoparticle-liposome drug delivery system that can be activated by near-infrared laser light to enable local photo-thermal therapy and the release of chemotherapeutic agents, which could achieve combined therapeutic efficiency. Methods To exploit the magnetic potential of iron oxide, we prepared and characterized citric acid-coated iron oxide magnetic nanoparticles (CMNPs) and encapsulated them into thermo-sensitive liposomes (TSLs). The chemotherapeutic drug, doxorubicin (DOX), was then loaded into the CMNP-TSLs, which were coated with an antibody against the epidermal growth factor receptor (EGFR), cetuximab (CET), to target EGFR-expressing breast cancer cells in vitro and in vivo studies in mouse model. Results The resulting CET-DOX-CMNP–TSLs were stable with an average diameter of approximately 120 nm. First, the uptake of TSLs into breast cancer cells increased by the addition of the CET coating. Next, the viability of breast cancer cells treated with CET-CMNP-TSLs and CET-DOX-CMNP-TSLs was reduced by the addition of photo-thermal therapy using near-infrared (NIR) laser irradiation. What is more, the viability of breast cancer cells treated with CMNP-TSLs plus NIR was reduced by the addition of DOX to the CMNP-TSLs. Finally, photo-thermal therapy studies on tumor-bearing mice subjected to NIR laser irradiation showed that treatment with CMNP-TSLs or CET-CMNP-TSLs led to an increase in tumor surface temperature to 44.7°C and 48.7°C, respectively, compared with saline-treated mice body temperature ie, 35.2°C. Further, the hemolysis study shows that these nanocarriers are safe for systemic delivery. Conclusion Our studies revealed that a combined therapy of photo-thermal therapy and targeted chemotherapy in thermo-sensitive nano-carriers represents a promising therapeutic strategy against breast cancer.

show abstract

Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone

Cited by 11 publications

References 27 publications

WITHDRAWN: Multiple Pulmonary Metastases of Giant Cell Tumor of Bone with expression of VEGFR-2 Successfully Treated by Denosumab and Apatinib: A Rare Case Report

WITHDRAWN: Multiple Pulmonary Metastases of Giant Cell Tumor of Bone with expression of VEGFR-2 Successfully Treated by Denosumab and Apatinib: A Rare Case Report

Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis

<p>Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy</p>

Contact Info

Product

Resources

About